Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A
Public ClinicalTrials.gov record NCT03447769. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of the study was to compare the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages II -IIIA according to the 8th edition of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) and the subset of IIIB (T\>5cm N2 disease) completely resected (R0) non-small cell lung cancer (NSCLC).
Study identification
- NCT ID
- NCT03447769
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,382 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 16, 2018 (Actual)
- Primary completion
- Mar 17, 2022 (Actual)
- Completion
- Feb 7, 2023 (Actual)
- Last update posted
- Oct 9, 2024
2018 – 2023
United States locations
- U.S. sites
- 21
- U.S. states
- 12
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group . | Fayetteville | Arkansas | 72703 | — |
| Cancer and Blood Specialty Clinic | Los Alamitos | California | 90720 | — |
| University of California at Los Angeles | Los Angeles | California | 90095 | — |
| VA Palo Alto Health Care System CRLX030A2301 | Palo Alto | California | 94304-1207 | — |
| Sansum Clinic | Santa Barbara | California | 93105 | — |
| Rocky Mountain Cancer Centers Denver-Mdtn(Bone&MarrowTransp) | Longmont | Colorado | 80501 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33901 | — |
| Advanced Medical Specialties Drug Ship - 2 | Miami | Florida | 33176 | — |
| Florida Cancer Affiliates of Ocala | Ocala | Florida | 34474 | — |
| Florida Cancer Specialists North | St. Petersburg | Florida | 33705 | — |
| Florida Cancer Specialists | West Palm Beach | Florida | 33401 | — |
| Rush University Medical Center Regulatory | Chicago | Illinois | 60612 | — |
| Cancer Center of Kansas Dept.ofCancerCtr.ofKansas | Wichita | Kansas | 67214-3728 | — |
| VA Nebraska-W IA Health Care System . | Omaha | Nebraska | 68105 | — |
| Louis Stokes Cleveland Department of Veterans Affairs MC . | Cleveland | Ohio | 44106 | — |
| Oncology Associates of Oregon, PC | Eugene | Oregon | 97401-8122 | — |
| Chattanooga Oncology and Hematology Associates PC Chattanooga Oncology | Chattanooga | Tennessee | 37404 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Texas Oncology MamieMcFaddenWardCtr | Dallas | Texas | 75246 | — |
| Virginia Cancer Specialists Fairfax Northern Virginia | Fairfax | Virginia | 22031 | — |
| Oncology and Hematology Associates of Southwest Virginia Inc . | Salem | Virginia | 24153 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 262 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03447769, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 9, 2024 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03447769 live on ClinicalTrials.gov.